No business profile yet.
Size ACRO Biomedical (6748.TWO) is a Taiwan Health Care company (Medical Specialties) with a market value of $377M, the 529th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$178.00 on 18 Nov 2026.
Performance Over six months the shares gained 158.0%, against -18.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 44.5% over the last twelve months (peer median +7.1%); the operating margin is -178.3% (peer median 12.2%).
Valuation It trades at 218.3× enterprise value to sales against a peer median of 2.7× (most expensive of 21).
Capital Return on invested capital runs 46.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$52.8M | NT$38.3M | NT$44.2M | NT$51.1M | NT$27.6M |
| Revenue growth | — | -14% | -13% | +85% | — |
| Gross profit | NT$28.0M | NT$12.2M | NT$17.8M | NT$31.0M | NT$7.37M |
| EBITDA | -NT$78.2M | -NT$75.7M | -NT$51.2M | -NT$37.7M | -NT$53.6M |
| Net income | -NT$78.8M | -NT$82.7M | -NT$62.1M | -NT$41.4M | -NT$60.9M |
| Free cash flow | -NT$81.5M | -NT$61.8M | -NT$73.7M | -NT$68.6M | -NT$50.3M |
| Capital expenditure | NT$11.3M | NT$15.4M | NT$32.6M | NT$22.5M | NT$4.44M |
| Total debt | n/a | NT$10.6M | NT$15.8M | NT$21.7M | NT$11.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6748.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.5% | -11.6% | 6th highest of 21 |
| 6-month return | +158.0% | -18.1% | highest of 20 |
| Distance from 52-week high | -42.6% | -44.8% | 9th highest of 21 |
| Revenue growth (TTM) | +44.5% | +7.1% | 2nd highest of 21 |
| Operating margin | -178.3% | 12.2% | 2nd lowest of 21 |
| EV / Sales | 218.3× | 2.7× | most expensive of 21 |
| ROIC minus cost of capital | -46.2 pp | +7.3 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | 7.1× | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 1.4× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 3.9× | 9.6% | +5.6% |